|
|
| | Ethyl (R)-(-)-4-cyano-3-hydroxybutyate Basic information |
| | Ethyl (R)-(-)-4-cyano-3-hydroxybutyate Chemical Properties |
| alpha | -5 º (neat) | | Boiling point | 270 °C(lit.) | | density | 1.114 g/mL at 25 °C(lit.) | | refractive index | n20/D 1.448(lit.) | | Fp | >230 °F | | storage temp. | 2-8°C | | solubility | Chloroform (Sparingly), DMSO (Slightly), Methanol (Slightly) | | form | Liquid | | pka | 13.03±0.20(Predicted) | | color | Colorless to yellow | | Specific Gravity | 1.114 | | optical activity | [α]25/D 5°, neat | | BRN | 5328715 | | InChIKey | LOQFROBMBSKWQY-ZCFIWIBFSA-N | | CAS DataBase Reference | 141942-85-0(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 1 | | HS Code | 29269090 |
| | Ethyl (R)-(-)-4-cyano-3-hydroxybutyate Usage And Synthesis |
| Chemical Properties | yellow liquid | | Uses | (3R)-4-Cyano-3-hydroxybutanoic Acid Ethyl Ester is used in a biocatalytic process for the synthesis of an atorvastatin intermediate and degredation products/impurities. | | Uses | analgesic, antipyretic, and anti-inflammatory | | Application | Hydroxyglutaryl coenzyme A (HMG-CoA) reductase inhibitors are a new class of lipid-lowering drugs, and they have a market share of more than 10 billion US dollars in the current pharmaceutical field. They can selectively inhibit the rate-limiting enzyme HMG-CoA reductase in cholesterol synthesis in the liver, reduce liver lipoprotein production, and increase the expression of low-density lipoprotein (LDL) cholesterol receptors, thereby reducing plasma cholesterol levels. They can also significantly reduce very low-density lipoprotein (VLDL) and triglycerides, and increase anti-atherosclerotic high-density protein (HDL), preventing atherosclerosis and coronary heart disease.
Ethyl (R)-(-)-4-cyano-3-hydroxybutyate is an important intermediate for the synthesis of HMG-CoA reductase inhibitors. If it is used as a raw material, synthetic atorvastatin is mainly used for the treatment of hypercholesterolemia and mixed hyperlipidemia, coronary heart disease and stroke. |
| | Ethyl (R)-(-)-4-cyano-3-hydroxybutyate Preparation Products And Raw materials |
|